Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Louisiana's legal battle over mail-order abortion pills is back in the spotlight as the 5th U.S. Circuit Court of Appeals hears arguments. The state's attorney general is pushing to overturn a Biden-era FDA rule that expanded telehealth access to mifepristone. A ruling against the policy could ripple far beyond Louisiana, threatening abortion access across the country.
Louisiana's attorney general is taking aim at a Biden-era FDA rule that allowed mifepristone — a widely used abortion drug — to be prescribed via telehealth and delivered by mail. The 5th U.S. Circuit Court of Appeals is hearing arguments, with the state arguing that the policy violates Louisiana's abortion ban and that out-of-state doctors prescribing the drug remotely are acting illegally. The case has already seen dramatic twists: the 5th Circuit previously froze the FDA rule, only for the Supreme Court to temporarily restore telehealth access while the underlying case plays out.
The stakes are high. If Louisiana prevails, the ruling could curtail telehealth abortion access nationwide — not just in states with bans. Meanwhile, Trump's FDA nominee Heidi Overton has publicly criticized mifepristone access, calling it "teleabortion" and advocating for stricter regulation, adding a political dimension to an already charged legal fight.
Why it matters: This case could set a precedent that reshapes how — and whether — patients across the U.S. can access abortion medication without an in-person visit, at a time when telehealth has become a critical pathway for reproductive care.
